Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors

Simona Dedoni, Luisa Marras, Maria C. Olianas, Angela Ingianni, and Pierluigi Onali

Laboratory of Cellular and Molecular Pharmacology, Section of Neurosciences, Department of Biomedical Sciences (S.D., M.C.O., P.O.) and Section of Microbiology, Department of Biomedical Sciences (L.M., A.I.), University of Cagliari, Cagliari, Italy

Received March 15, 2019; accepted June 14, 2019

ABSTRACT

Valproic acid (VPA) has been shown to regulate the levels of brain-derived neurotrophic factor (BDNF), but it is not known whether this drug can affect the neuronal responses to BDNF. In the present study, we show that in retinoic acid-differentiated SH-SYSY human neuroblastoma cells, prolonged exposure to VPA reduces the expression of the BDNF receptor TrkB at the protein and mRNA levels and inhibits the intracellular signaling, neurotrophic activity, and prosurvival function of BDNF. VPA downregulates TrkB and curtails BDNF-induced signaling also in differentiated Kelly and LAN-1 neuroblastoma cells and primary mouse cortical neurons. The VPA effect is mimicked by several histone deacetylase (HDAC) inhibitors, including the class I HDAC inhibitors entinostat and romidepsin. Conversely, the class II HDAC inhibitor MC1568, the HDAC6 inhibitor tubacin, the HDAC8 inhibitor PCI-34051, and the VPA derivative valpromide have no effect. In neuroblastoma cells and primary neurons both VPA and entinostat increase the cellular levels of the transcription factor RUNX3, which negatively regulates TrkB gene expression. Treatment with RUNX3 siRNA attenuates VPA-induced RUNX3 elevation and TrkB downregulation. VPA, entinostat, HDAC1 depletion by siRNA, and 3-deazaneplanocin A (DZNep), an inhibitor of the polycistrionic repressor complex 2 (PRC2), decrease the PRC2 core component EZH2, a RUNX3 suppressor. Like VPA, HDAC1 depletion and DZNep increase RUNX3 and decrease TrkB expression. These results indicate that VPA downregulates TrkB through epigenetic mechanisms involving the EZH2/RUNX3 axis and provide evidence that this effect implicates relevant consequences with regard to BDNF efficacy in stimulating intracellular signaling and functional responses.

SIGNIFICANCE STATEMENT

The tropomyosin-related kinase receptor B (TrkB) mediates the stimulatory effects of brain-derived neurotrophic factor (BDNF) on neuronal growth, differentiation, and survival and is highly expressed in aggressive neuroblastoma and other tumors. Here we show that exposure to valproic acid (VPA) downregulates TrkB expression and functional activity in retinoic acid-differentiated human neuroblastoma cell lines and primary mouse cortical neurons. The effects of VPA are mimicked by other histone deacetylase (HDAC) inhibitors and HDAC1 knockdown and appear to be mediated by an epigenetic mechanism involving the upregulation of RUNX3, a suppressor of TrkB gene expression. TrkB downregulation may have relevance for the use of VPA as a potential therapeutic agent in neuroblastoma and other pathologies characterized by an excessive BDNF/TrkB signaling.

Introduction

The short-chain branched fatty acid valproic acid (VPA) is commonly used in the clinic as an anticonvulsant for the treatment of various forms of epilepsy, as a mood stabilizer for the management of bipolar mood disorder, and as an analgesic for migraine headaches (Loscher, 2002). Moreover, in clinical trials VPA has been investigated as a potential anticancer agent for both hematologic and solid tumors (Chateauvieux et al., 2010). This wide array of pharmacological properties likely stems from the ability of VPA to display multiple mechanisms of action, including inhibition of voltage-gated sodium and calcium channels, potentiation of GABAergic transmission, attenuation of glutamatergic function, and alteration of the activity of distinct intracellular signaling mediators (Loscher, 2002). Moreover, VPA at clinically relevant concentrations has been demonstrated to act as an effective inhibitor of histone deacetylases (HDACs) (Gottlicher et al., 2001; Phiel et al., 2001), which play a critical role in the epigenetic regulation of gene transcription (Thiagalingam et al., 2003; Bolden et al., 2006). Among the four distinct classes of mammalian HDACs so far identified, VPA preferentially inhibits HDACs belonging to class I and IIa (Bolden et al., 2006).

A number of preclinical studies have shown that VPA can exert neuroprotective effects against a variety of brain insults, suggesting a therapeutic potential in different neurodegenerative conditions.
Inhibition of TrkB Expression by Valproic Acid

Valproic Acid (VPA), a broad-spectrum histone deacetylase (HDAC) inhibitor, has demonstrated neuroprotective effects in a variety of animal and clinical trials. However, the underlying mechanisms for its neuroprotective effects remain poorly understood. In this study, we aimed to investigate the effect of VPA on the expression of brain-derived neurotrophic factor (BDNF), a critical protein for neuronal growth, differentiation, and survival. BDNF signaling plays a crucial role in the development and function of the nervous system, including roles in cell survival, differentiation, and plasticity.

Materials and Methods

Materials. Recombinant human BDNF was obtained from Alomone Laboratories (Jerusalem, Israel). Ectinostat (MS-275, pyridine-3-ylmethyloxazol-2-yl-N-[4-[(2-aminophenyl) carbamoyl] phenyl] methylcarbamate) and valproamide were obtained from Santa Cruz Biotechnology (Dallas, TX). MC1568 (3-[5-(3-fluorophenyl)-3-oxopropen-1-yl]-1-methyl-1H-pyrrrol-2-yl]-N-hydroxy-2-ropename) was from SelleckChem (Houston, TX).

In vitro studies using primary cultures of rat cortical neurons have shown that BDNF expression induced by either VPA or the HDAC inhibitors sodium butyrate and trichostatin A was associated with increased histone acetylation and mimicked by silencing of HDAC1 gene (Yasuda et al., 2009). A microarray analysis of gene expression in cultured rat cortical neurons revealed that BDNF was among the 726 genes upregulated by VPA exposure (Fukuchi et al., 2009). The ability of VPA to target BDNF transcription may have pharmacological relevance, since alterations of BDNF signaling have been associated with several neuropathological conditions, including epilepsy, affective disorders, and pain, which are clinically treated with VPA (Autry and Monteggia, 2012).

In contrast to the large amount of information available on the regulation of BDNF by VPA, relatively little is known on the effects of this drug on TrkB, the receptor that mediates the biologic actions of BDNF (Chao, 2003; Huang and Reichardt, 2003). Upon binding of neurotrophin homodimers, TrkB, which belongs to the tyrosine kinase receptor family, dimerizes, autophosphorylates, and activates three main signaling pathways, including phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (Akt), phospholipase C γ (PLCγ), and extracellular signal-regulated kinases 1 and 2 (ERK1/2). A number of studies have shown that an efficient activation of each of these pathways is ultimately responsible for the correct control of neuronal growth, differentiation, and survival by the BDNF/TrkB receptor complex (Chao, 2003; Huang and Reichardt, 2003).

The transcriptional regulation of Trk receptor expression is known to be under control of different transcription factors (Lei and Parada, 2007). In developing sensory neurons and human neuroblastoma cells, RUNX3, a runt domain transcription factor, has been shown to selectively repress TrkB expression (Kramer et al., 2006; Inoue et al., 2007). In different cell types the RUNX3 gene is epigenetically silenced by the histone methyltransferase EZH2, a core component of the polycomb repressive complex 2 (PRC2), which has been found to interact and cooperate with class I HDACs (van der Vlag and Otte, 1999; Varambally et al., 2002; Fujii et al., 2008). HDAC inhibitors have been shown to cause depletion of PRC2 proteins and the consequent RUNX3 de-repression (Fiskus et al., 2006; Wang et al., 2012).

To investigate the effect of VPA on TrkB expression and functional activity, we employed human neuroblastoma cell lines, in which TrkB is induced by treatment with retinoic acid (Kaplan et al., 1993), and primary cultures of mouse cortical neurons, which endogenously express the receptor. We also examined whether in these cells VPA could alter the expression of the EZH2/RUNX3 regulatory axis.

Materials and Methods

Materials. Recombinant human BDNF was obtained from Alomone Laboratories (Jerusalem, Israel). Ectinostat (MS-275, pyridine-3-ylmethyloxazol-2-yl-N-[4-[(2-aminophenyl) carbamoyl] phenyl] methylcarbamate) and valproamide were obtained from Santa Cruz Biotechnology (Dallas, TX). MC1568 (3-[5-(3-fluorophenyl)-3-oxopropen-1-yl]-1-methyl-1H-pyrrrol-2-yl]-N-hydroxy-2-ropename) was from SelleckChem (Houston, TX).
orthovanadate, 10 mM sodium fluoride, 1 mM PMSF, 0.5% phosphatase inhibitor cocktail 3 and 1% protease inhibitor cocktail. Following centrifugation at 3000 g for 10 minutes at 4°C, the nuclei present in the pellets were washed and the proteins were extracted by incubating the nuclei on ice for 30 minutes in a buffer containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid/NaOH, 300 mM NaCl, 2 mM MgCl₂, 0.2 mM EDTA, 2 mM sodium orthovanadate, 10 mM sodium fluoride, 1 mM PMSF, 0.5% phosphatase inhibitor cocktail 3 and 1% protease inhibitor cocktail (pH 7.9). Following centrifugation at 24,000 g for 10 minutes at 4°C, the nuclear extracts were mixed with sample buffer and analyzed by Western blot.

**RNA Transfection of Small Interfering RNA.** SH-SY5Y cells were transfected with either 50 pmol/ml of control small interfering RNA (siRNA)-A (sc-29343; Santa Cruz Biotechnology), or RUNX3 siRNA (sc-37679; Santa Cruz Biotechnology) duplexes using Lipofectamine RNAiMAX (Invitrogen) as a transfection reagent. Control siRNA consisted of a nontargeting sequence. Cells grown in six-well plates were incubated in antibiotic-free medium for 24 hours. The medium was renewed and the cells were incubated with siRNA duplexes for 4 to 5 hours at 37°C. Thereafter, the medium was replaced by the growth medium, and the cells were analyzed 48 hours posttransfection. To determine transfection efficiency, parallel samples were transfected with fluorescein-conjugated control siRNA-A (sc-36869; Santa Cruz Biotechnology). An efficiency of 50%–60% was obtained in six separate experiments.

**RNA Extraction and Quantitative Polymerase Chain Reaction.** SH-SY5Y cells were incubated in a medium containing 1% FCS and treated for 24 hours with either vehicle or 1 mM VPA. Thereafter, the cells were washed with PBS and total RNA was isolated by using TRIzol reagent (Invitrogen) with the PureLink RNA mini kit as specified by the manufacturer’s protocol. After RNA purification a Turbo DNase (Ambion by Life Technologies) digestion was performed. The purity and quantity of the RNA isolated were determined by measuring UV absorbance at 260 and 280 nm.

First-strand cDNA synthesis was performed using 2 μg of total RNA, following the manufacturer’s protocol (SuperScript VILO cDNA synthesis kit; Invitrogen). Two-hundred nanograms of cDNA for reaction was used for quantitative polymerase chain reaction amplification with SYBR Green PCR Master Mix (Applied Biosystems). The quantitative polymerase chain reaction analysis was carried out on a real-time PCR system (StepOne; Applied Biosystems) under the following conditions: an initial holding stage at 95°C for 10 minutes was followed by 45 cycles: denaturation at 95°C for 15 seconds, primer annealing and extension at 60°C for 1 minute, and a dissociation curve to the end of a real time run (melting curve 95°C for 15 seconds, 60°C for 1 minute and 95°C for 15 seconds). The PCR primers used were: human TrkB (NCBI accession number NM_006180.3) forward ACAGTCAGCTCAAGCCAGACAC, reverse CATGCCGGAGCCGTTGTCGAC. The comparative Ct values were obtained according to the manufacturer’s protocol.

**Immunofluorescence Analysis.** Differentiated SH-SY5Y cells grown on poly-L-lysine-coated coverslips were treated with the test agents as indicated in the text, washed, and fixed in 4% paraformaldehyde for 5 minutes at 4°C, and the supernatants were incubated overnight with streptavidin-conjugated agarose beads with continuous rotation at 4°C. The samples were then centrifuged to obtain a supernatant and a pellet fraction containing the plasma membrane-associated proteins. The agarose beads were washed three times with ice-cold Tris buffer containing 10 mM Tris-HCl (pH 7.5), 2.5 mM EDTA, 150 mM NaCl, and 1% Triton x 100, followed by two washes with 10 mM Tris-HCl (pH 7.5), 2.5 mM EDTA, 500 mM NaCl, and 0.1% Triton x 100 and one final wash with 50 mM Tris-HCl (pH 7.5). The pellets were then mixed with sample buffer and incubated 2 minutes at 100°C. The proteins were then analyzed by Western blot.

**Western Blot Analysis.** Cell proteins were separated by SDS-polyacrylamide gel and electrophoretically transferred to polyvinylidene difluoride membranes (Amersham Biosciences, Piscataway, NJ). Membranes were blocked, washed, and incubated overnight at 4°C with one of the following primary antibodies: TrkB (cat. no. 4603; Cell Signaling Technology, Danvers, MA) (1:1000), TrkA (cat. no. 2508; Cell Signaling Technology) (1:1000), TrkC (cat. no. 3376; Cell Signaling Technology) (1:1000), phospho-TrkA (Ytr674/675)/TrkB (Ytr706/707) (cat. no. 4621; Cell Signaling Technology) (1:1000), p75NTR (cat. no. 8238; Cell Signaling Technology) (1:1000), synapsin-1 (cat. no. 5297; Cell Signaling Technology) (1:2000), pan-cadherin (cat. no. 4073; Cell Signaling Technology) (1:1000), phospho-S6 ribosomal protein (Ser235/236) (cat. no. 4856; Cell Signaling Technology), S6 ribosomal protein (cat. no. sc-74459; Santa Cruz Biotechnology) (1:1000), phospho-Akt (Thr308) (cat. no. 2965; Cell Signaling Technology) (1:1000), Akt1/2 (cat. no. sc-8312; Santa Cruz Biotechnology) (1:1000), phospho-glycogen synthase kinase (GSK)-3β (Ser9) (cat. no. 9356; Cell Signaling Technology) (1:1000), GSK-3β (cat. no. sc-9166; Santa Cruz Biotechnology) (1:1000), extracellular signal-regulated kinases 1 and 2 (ERK1/2) (cat. no. 9102; Cell Signaling Technology) (1:1000), phospho-ERK1 (Thr202/Tyr204)/ERK2 (Thr185/Tyr187) (cat. no. RA15002; NeuroMics, Northfield, MN) (1:15,000), phospholipase C-γ1 (PLC-γ1) (cat. no. 2822; Cell Signaling Technology) (1:1000), phospho-PLC-γ1 (Y783) (cat. no. 2821; Cell Signaling Technology) (1:1000), cleaved-poly(ADP-ribose) polymerase (PARP) (Asp214) (cat. no. 5625; Cell Signaling Technology) (1:1000), PARP (cat. no. 9542; Cell Signaling Technology) (1:1000), enhancer of zeste homolog 2 (EZH2) (cat. no. 5246; Cell Signaling Technology) (1:2000), RUNX3AML2 (cat. no. 9647; Cell Signaling Technology) (1:1000), posttranscriptional density 95 (P5D95) (cat. no. 3450; Cell Signaling Technology) (1:2000), GluK1 (cat. no. 2040; Torcis Cookson Ltd., Avonmouth, UK) (1:1000), HDAC1 (cat. no. sc-81598; Santa Cruz Biotechnology) (1:5000), histone H3 (cat. no. GTX122148; GeneTex Inc., Irvine, CA) (1:2000), histone H3 (acetyl-Lys9/Lys14) (cat. no. GTX122648; GeneTex Inc.) (1:1000), MAP2 (cat. no. 180011; Synaptic Systems GmbH, Göttingen, Germany) (1:1000), actin (cat. no. A2066; Sigma-Aldrich) (1:3000), active (cat. no. A5441; Sigma-Aldrich) (1:20,000), anglyceraldehyde 3-phosphate dehydrogenase (GAPDH) (cat. no. 247002; Synaptic Systems GmbH) (1:1000). Thereafter, the membranes were washed and incubated with an appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology). Immunoreactive bands were detected using Clarity Western ECL substrate (Bio-Rad Laboratory.) and ECL Hyperfilm (Amersham). The size of immunoreactive bands was determined by using molecular weight standards detected with an ECL suitable antibody (cat. no. sc-2035; Santa Cruz Biotechnology) (1:1000). Band densities were determined using Image Scanner III (GE Healthcare, Milan, Italy) and NIH ImageJ software (US National Institutes of Health, Bethesda, MA). The optical density of the phosphorylated protein bands was normalized to the density of the corresponding total protein. For analysis of PARP, the formation of the cleaved protein was normalized to the level of the uncleaved PARP determined in the same samples. For the remaining proteins, the densitometric values were normalized to the levels of either actin, GAPDH, or subcellular fraction marker, as indicated.

**Immunofluorescence Analysis.** Differentiated SH-SY5Y cells grown on poly-L-lysine-coated coverslips were treated with the test agents as indicated in the text, washed, and fixed in 4% paraformaldehyde for...
Inhibition of TrkB Expression by Valproic Acid

30 minutes at room temperature. For analysis of TrkB, nonpermeabilized cells were blocked with 3% BSA and 1% normal goat serum and incubated overnight with an antibody directed against an extracellular domain of TrkB (1:50) (cat. no. ANT-019; Alomone Laboratories). For analysis of neuritogenesis and detection of cleaved-caspase 3, cells were permeabilized with 0.2% Triton X-100, blocked, and incubated overnight at 4°C with mouse anti-actin (cat. no. A5441; Sigma-Aldrich) (1:5000) and rabbit anti-cleaved caspase-3 (cat. no. 9661; Cell Signaling Technology) (1:200), respectively.

Cells were then incubated with an appropriate Alexa-Fluor488- or Alexa-Fluor594-conjugated secondary antibody (Invitrogen-Molecular Probes), and cell nuclei were stained with 0.1 μg/ml 4',6-diamidino-2-phenylindole. Cells were analyzed with an Olympus BX61 microscope equipped with a F-View II CCD-camera by using either a ×40 or a ×60 objective lens. Digital images were acquired using constant camera settings within each experiment and were analyzed using the program Cell P (Olympus Soft Imaging Solutions, Homburg, Germany). At least 15 fields were randomly selected for each sample, and only cells showing an unobstructed nucleus or soma were considered.

For quantification of neuritogenesis, at least 10 fields were analyzed for each sample run in triplicate and in each field the cell bodies and neurites were counted. Processes with length equal to two or more cell body diameters were scored as neurites. The ratio of neurites to cell bodies was calculated and expressed as mean ± S.E.M. Four separate preparations of SH-SY5Y cells were examined. For analysis of TrkB and cleaved caspase 3 expression, the average pixel intensity was measured within the region of the cell soma or the nucleus and in an adjacent area, which was used as background value. Cells were deemed to be positive if the average pixel intensity was equal or above a threshold value corresponding to 1 S.D. above the average pixel intensity of the respective control samples (Dedoni et al., 2017). No labeling was detected in samples treated without the cell soma or the nucleus and in an adjacent area, which was used as a control.

Results

VPA Downregulates TrkB Expression in RA-Differentiated Neuroblastoma Cells. In agreement with previous studies (Kaplan et al., 1993; Encinas et al., 1999; Dedoni et al., 2012), Western blot analysis of TrkB expression in RA-differentiated SH-SY5Y cells detected the presence of an immunoreactive band of 145 kDa representing the catalytic tyrosine kinase full-length isoform of TrkB (TrkB-FL) and an additional broader band of 95 kDa, which corresponded to the molecular mass of the truncated TrkB (TrkB-T) isofoms TrkB.T1 and TrkB.T2 lacking the tyrosine kinase domain (Fig. 1A) (Klein et al., 1990; Stoilov et al., 2002). Prolonged (24 hours) cell treatment with VPA (1 mM) reduced the expression levels of the 145- and 95-kDa isoforms by 63% ± 6% and 47% ± 5% (P < 0.001, N = 6), respectively (Fig. 1A). Quantitative RT-PCR analysis indicated that VPA reduced the level of TrkB mRNA by 45% ± 5% (P < 0.001, N = 3) (Fig. 1B).

We also investigated the effects of VPA on other neurotrophin receptors whose expression is known to be enhanced by RA treatment of neuroblastoma cells. Prolonged exposure using the program Graph Pad Prism 5 (San Diego, CA). Unless otherwise indicated, data are expressed as percentage or fold stimulation of control, which was included in each independent experiment. The control group was set as 100 or 1, with a variance obtained by expressing each control value as a percentage of the mean of the raw values of the control group. In the experiments in which control values were equal to zero, values of experimental groups were expressed as a percentage of the maximal effect set as 100. The variance of this value was determined in the same manner as for the control group. Statistical analysis was performed by either Student’s unpaired t test or one-way analysis of variance followed by Newman-Keuls post hoc test as appropriate. A value of P < 0.05 was considered to be statistically significant.

Fig. 1. VPA downregulates TrkB expression in RA-differentiated neuroblastoma cells. (A) SH-SY5Y cells were incubated for 24 hours with either vehicle or 1 mM VPA, and the expression of full length (TrkB-FL) and truncated (TrkB-T) isoforms of TrkB was analyzed by Western blot and normalized to actin levels. Values are the mean ± S.E.M. of six independent experiments. (B) Quantitative real-time RT-PCR analysis of TrkB mRNA in SH-SY5Y cells treated for 24 hours with either vehicle or 1 mM VPA. Values are the mean ± S.E.M. of three independent determinations. (C–E) SH-SY5Y cells were treated as in (A), and the expression of TrkA (C), TrkC (D), and p75NTR (E) was determined in cell lysates. (F and G) Kelly (F) and LAN-1 (G) cells were treated for 24 hours with either vehicle or VPA (1 mM). Cell lysates were then analyzed for TrkB expression. Values are the mean ± S.E.M. of four (Kelly) and seven (LAN-1) experiments. *P < 0.05; **P < 0.001 vs. control (vehicle) by Student’s t test.
of differentiated SH-SY5Y cells to VPA (1 mM) failed to significantly affect the protein levels of TrkA, the receptor of nerve growth factor (Fig. 1C), but markedly enhanced the expression of the full-length and truncated isoforms of TrkC, the receptor for neurotrophin 3 (Fig. 1D), and the common neurotrophin receptor p75NTR (Fig. 1E). Densitometric values of vehicle- and VPA-treated samples (expressed as fold changes with respect to vehicle set to 1.0) were: TrkA 1.28 ± 0.05 (P > 0.05, N = 4); TrkC-FL 20 ± 3, TrkC-T 6.5 ± 1.0 (P < 0.001 N = 3); p75NTR 50 ± 8 (P < 0.001, N = 6).

We examined the effects of VPA on TrkB expression in two additional human neuroblastoma cell lines, LAN-1 and Kelly, which, differently from SH-SY5Y cells, display MYCN oncogene amplification. Both Kelly and LAN-1 cells predominantly expressed the TrkB-FL isoform upon RA exposure (Supplemental Fig. 1). Treatment with VPA (1 mM) for 24 hours decreased the levels of TrkB-FL by 46% ± 5% (P < 0.001, N = 4) and 32% ± 4% (P < 0.05, N = 7) in Kelly and LAN-1 cells, respectively (Fig. 1, F and G).

The VPA inhibition of TrkB expression was time dependent, being significant after 6 hours of treatment and increasing progressively up to 24 hours (Fig. 2A). The inhibitory effect was also concentration dependent, being absent at 0.1 and 0.3 mM VPA and increasing as the drug concentrations were elevated from 0.6 to 3 mM (Fig. 2B). To investigate whether VPA affected the plasma membrane expression of TrkB, surface protein biotinylation experiments were performed in SH-SY5Y cells. As shown in Fig. 3A, exposure to VPA (1 mM) reduced the cell surface levels of TrkB-FL and TrkB-T by 65% ± 6% and 47% ± 5% (P < 0.001, N = 4), respectively, compared with vehicle-treated cells. Moreover, immunofluorescence analysis of TrkB in nonpermeabilized cells, using an antibody directed against an extracellular domain of the receptor to detect its plasma membrane expression, indicated that VPA treatment decreased the percentage of TrkB-positive cells by 64% ± 4% (P < 0.001, N = 4) (Fig. 3B).

VPA Exposure Inhibits BDNF-Induced TrkB Activation and Signaling. BDNF-induced TrkB activation involves the receptor autophosphorylation at distinct tyrosine residues located in the intracytoplasmatic domain, which regulates the receptor activity and allows the docking of adaptor signaling molecules. Exposure of SH-SY5Y cells to VPA (1 mM) induced a marked inhibition of BDNF (1 nM)-induced TrkB phosphorylation at Tyr706/707, which occurs within the activation loop of the catalytic domain and enhances the integral receptor tyrosine kinase activity (Huang and Reichardt, 2003) (Fig. 4A). The inhibitory effect of VPA remained significant when phospho-tyrosine kinase activity (Huang and Reichardt, 2003) (Fig. 4A).

VPA treatment markedly reduced the ability of BDNF to trigger the activation of PLCγ and PI3K/Akt signaling pathways, which are predominantly involved in the promotion of synaptic

---

**Fig. 2.** Time- and concentration-dependent inhibition of TrkB expression by VPA. (A) SH-SY5Y cells were incubated in the presence of 1 mM VPA for the indicated periods of time. Zero time samples were treated with vehicle and used as control. (B) SH-SY5Y cells were incubated for 24 hours in the presence of either vehicle or VPA at the indicated concentrations. Cell lysates were analyzed for TrkB expression. Values are the mean ± S.E.M. of four experiments. *P < 0.05, ***P < 0.001 vs. control (vehicle) by analysis of variance (ANOVA) followed by Newman-Keuls post hoc test.

**Fig. 3.** VPA reduces plasma membrane expression of TrkB. SH-SY5Y cells were treated with either vehicle or VPA (1 mM) for 24 hours. Cells were then exposed to the cell impermeant biotinylating agent sulfoSAEC-6-biotin-amido-6-choic acid and solubilized proteins were precipitated by streptavidin-conjugated agarose beads. The precipitate (surface protein) and total extract (cell lysate) were analyzed for TrkB by Western blot (A). TrkB levels in the surface protein preparation were normalized to pan-cadherin levels, a plasma membrane (membr) marker. Densitometric values are expressed as percent of control (vehicle) and are the mean ± S.E.M. of four experiments. (B) TrkB expression was analyzed by immunofluorescence (green color) in nonpermeabilized cells with an antibody directed against an extracellular domain of the receptor. Nuclei were stained in blue with 4′,6-diamidino-2-phenylindole (DAPI). Values are the mean ± S.E.M. of four experiments. Scale bar, 25 μm. ***P < 0.001 vs. control (vehicle) by Student’s t test.
plasticity and neuronal survival, respectively (Huang and Reichardt, 2003). In SH-SY5Y, cells pre-exposed to VPA (1 mM) showed a 67% reduction in the phosphorylation of PLC\(\gamma_1\) at Tyr783, which is essential for neurotrophin-induced PLC\(\gamma_1\) activation (Kim et al., 1991), while VPA inhibited the BDNF-induced phosphorylation of Akt by 46% (P < 0.001, N = 4) (Fig. 4C) and phosphorylation of the Akt substrate GSK-3\(\beta\) at Ser9 by 40% (P < 0.001, N = 4) (Fig. 4D).

Activation of ERK1/2 constitutes another major signaling pathway activated by the BDNF-TrkB receptor complex. As shown in Fig. 4, E and F, in SH-SY5Y cells, BDNF (0.05 and 0.1 nM) stimulated the phosphorylation of ERK1/2 and the downstream ERK1/2 target S6 ribosomal protein in a concentration-dependent manner, and these responses were markedly reduced in cells pre-exposed to VPA.

VPA Reduces the Proneurotrophic and Antiapoptotic Activities of BDNF. The induction of TrkB following treatment with RA allows neuroblastoma cells to respond to BDNF with neuronal differentiation, as indicated by the appearance of morphologic changes and the enhanced expression of neuronal

![Inhibition of BDNF-induced TrkB activation and signaling by VPA.](image-url)
markers (Kaplan et al., 1993; Encinas et al., 1999; Dedoni et al., 2012). SH-SY5Y cells treated with RA mostly showed large cell bodies with a polygonal shape and short neurites (Fig. 5A), whereas the exposure of the cells to BDNF (1 nM) for 48 hours increased the percentage of cells with a smaller and rounded cell body and long neuritic processes. Cells treated with VPA (1 mM) for 72 hours displayed a morphology similar to that of vehicle-treated cells. However, when the cells were preincubated for 24 hours with VPA and then exposed to BDNF and VPA for 48 hours, there was a significant reduction in the percentage of neurite-bearing cells compared with cells treated with the neurotrophin alone (Fig. 5A).
The microtubule-associated protein 2 (MAP2) is a major component of the neuronal cytoskeleton and comprises proteins with high molecular mass (MAP2A and MAP2B, ~270 kDa) and low molecular mass (MAP2C, ~70 kDa) (Garner and Matus, 1988). Western blot analysis of MAP2 expression in RA-differentiated SH-SY5Y cells with an antibody that recognizes all three MAP2 forms detected a single immunoreactive band of ~70 kDa, indicating the presence of MAP2C. Prolonged exposure to BDNF increased the expression of MAP2 by about threefold, and this effect was prevented by pre-treatment with 0.6 and 1 mM VPA (Fig. 5B). Cell treatment with BDNF also enhanced the steady-state levels of synapsin-1 proteins (Fig. 5C), which regulate synaptogenesis and neurotransmitter release (Cesca et al., 2010), the glutamate AMPA receptor subunit GluR1 (Fig. 5D), and the scaffolding protein postynaptic density 95 (Fig. 5E). Cell pretreatment with VPA (0.6 and 1 mM) significantly curtailed these neurotrophic responses to BDNF.

Prolonged serum withdrawal induces apoptotic cell death of SH-SY5Y cells (Macleod et al., 2001; Dedoni et al., 2017). Addition of BDNF (1 nM) to the serum-free medium protected against apoptosis, as indicated by the significant decrease in the percentage of cleaved caspase 3-positive cells (Fig. 5F). In cells pretreated with VPA (1 mM), the pro-survival effect of BDNF was almost completely abrogated. In serum-starved cells BDNF also significantly reduced the levels of PARP cleaved at Asp 186, almost completely abrogated. In serum-starved cells BDNF also significantly reduced the levels of PARP cleaved at Asp 186, and this effect was prevented by pre-exposure to VPA (Fig. 5G).

**HDAC Inhibitors and HDAC1 Knockdown Mimic the Inhibitory Effect of VPA on TrkB Expression and Signaling.** We investigated whether epigenetic mechanisms were involved in the downregulation of TrkB induced by VPA. To this goal, we first examined whether other HDAC inhibitors could mimic the effect of VPA. As shown in Supplemental Fig. 2, A–D, incubation of RA-differentiated SH-SY5Y cells with either VPA (1 mM); trichostatin A (300 nM), a broad spectrum HDAC inhibitor (Bolden et al., 2006); the class I inhibitor entinostat (1 μM) (Saito et al., 1999; Hu et al., 2003); or MC 1568 (10 μM), a class II HDAC inhibitor (Mai et al., 2005), elicited a time-dependent increase in the acetylation of histone H3 at Lys9/Lys14, which became significant 1–3 hours after drug exposure. Prolonged cell treatment with either romidepsin (40 nM), a selective inhibitor of the class I members HDAC1 and 2, or the short-chain fatty acid sodium butyrate (1 mM), which shares with VPA the ability to preferentially block class I and IIa HDACs (Bolden et al., 2006), markedly increased H3 acetylation (Supplemental Fig. 2E). Both HDAC6 and HDAC8 have been found to be expressed in human neuroblastoma cells, and their specific inhibition by tubacin and PCI-34051, respectively, has been shown to inhibit the growth and viability of these cells (Subramanian et al., 2011; Rettig et al., 2015). Consistent with previous studies (Haggarty et al., 2003; Balasubramanian et al., 2008), we found that both tubacin and PCI-34051, used at concentrations low enough to maintain their HDAC selectivity, failed to induce H3 histone acetylation (Supplemental Fig. 2E). A lack of effect was also observed in cells treated with the carboxamide derivative of VPA valpromide (1 mM) (Supplemental Fig. 2E), which lacks HDAC inhibitory activity (Phiel et al., 2001).

As observed with VPA, prolonged exposure (24 hours) of differentiated SH-SY5Y cells to either sodium butyrate (1 mM), trichostatin A (300 nM), entinostat (1 μM), or romidepsin (40 nM) elicited a significant decrease in the expression of both TrkB-FL and TrkB-T isoforms (Fig. 6, A–C). Immunofluorescence assays indicated that entinostat (1 μM) decreased the percentage of TrkB-positive cells by 80% ± 4% (P < 0.001, N = 4) (Fig. 6D). Conversely, cell treatment with either MC1568 (10 μM) (Fig. 6A), PCI-34051 (4 μM), tubacin (5 μM), or valpromide (1 mM) failed to affect TrkB expression (Fig. 6, E and F). Like VPA, trichostatin A and sodium butyrate induced a significant inhibition of BDNF-induced Akt phosphorylation, whereas valpromide and MC 1568 were without effect (Fig. 6, G and H). Entinostat (0.5 and 1 μM) caused a concentration-dependent inhibition of BDNF-stimulated phosphorylation of Akt and ERK1/2 (Fig. 6I). Similarly, cell treatment with romidepsin (20 and 40 nM) induced a significant decrease of BDNF-induced phosphorylation of Akt and GSK-3β (Fig. 6J).

We next examined the effects of knocking down HDAC1, an HDAC isoform that regulates neuronal survival and death (Bardai et al., 2012) and is inhibited by therapeutically relevant concentrations of VPA (Phiel et al., 2001). As shown in Fig. 6K, treatment of differentiated SH-SY5Y cells with siRNA targeting HDAC1 decreased HDAC1 protein levels by 60% ± 12% (P < 0.05, N = 3) and increased the level of acetylated histone H3 by 70% ± 10% (P < 0.001, N = 3) compared with control siRNA-treated cells. In HDAC1-depleted cells there was a significant decrease in the expression of both TrkB-FL and TrkB-T (Fig. 6L).

**VPA Upregulates RUNX3 Expression.** To investigate the involvement of transcriptional mechanisms in VPA-induced downregulation of TrkB, we examined the effects of VPA on the transcription factor RUNX3, a suppressor of TrkB expression (Kramer et al., 2006; Inoue et al., 2007). As shown in Fig. 7, A and B, exposure of differentiated SH-SY5Y cells to VPA induced a time- and concentration-dependent increase in RUNX3 protein levels. These effects occurred within the same concentration range of VPA required to increase histone H3 acetylation (Fig. 7B) and were mirrored by similar changes in the steady-state nuclear content of the transcription factor (Fig. 7C). An increase of RUNX3 levels was also observed in Kelly and LAN-1 cells following exposure to either VPA (1 mM) or entinostat (1 μM) (Supplemental Fig. 3, A and B).

**Involvement of RUNX3 in VPA-Induced TrkB Down-regulation.** To investigate whether the enhanced expression of RUNX3 participates in TrkB downregulation by VPA, differentiated SH-SY5Y cells were transfected with siRNA duplexes targeting RUNX3. This treatment attenuated the increase in RUNX3 protein levels elicited by VPA and significantly reduced the downregulation of TrkB expression induced by the drug (Fig. 7D).

In human neuroblastoma cells, RUNX3 gene transcription has been reported to be under inhibitory control by the histone methyltransferase EZH2, the catalytic subunit of PRC2 (Wang et al., 2012). Exposure of RA-treated SH-SY5Y cells to VPA (1 mM) reduced EZH2 protein levels by 60% ± 5% (P < 0.001, N = 4) (Fig. 7E). Moreover, in these cells, TrkB downregulation induced by HDAC1 depletion was associated with a decrease of EZH2 and an increase of RUNX3 protein levels (Fig. 7F). A significant decrease of EZH2 was also observed in Kelly and LAN-1 cells following treatment with either VPA (1 mM) or entinostat (1 μM) (Supplemental Fig. 3, C and D).

To further investigate the involvement of the EZH2/RUNX3 axis in the regulation of TrkB expression, we examined the effects of the cyclopentenyl analog of 3-deazaadenosine inhibiting the involvement of transcriptional mechanisms in VPA-induced downregulation of TrkB, we examined the effects of VPA on the transcription factor RUNX3, a suppressor of TrkB expression (Kramer et al., 2006; Inoue et al., 2007). As shown in Fig. 7, A and B, exposure of differentiated SH-SY5Y cells to VPA induced a time- and concentration-dependent increase in RUNX3 protein levels. These effects occurred within the same concentration range of VPA required to increase histone H3 acetylation (Fig. 7B) and were mirrored by similar changes in the steady-state nuclear content of the transcription factor (Fig. 7C). An increase of RUNX3 levels was also observed in Kelly and LAN-1 cells following exposure to either VPA (1 mM) or entinostat (1 μM) (Supplemental Fig. 3, A and B).

**Involvement of RUNX3 in VPA-Induced TrkB Down-regulation.** To investigate whether the enhanced expression of RUNX3 participates in TrkB downregulation by VPA, differentiated SH-SY5Y cells were transfected with siRNA duplexes targeting RUNX3. This treatment attenuated the increase in RUNX3 protein levels elicited by VPA and significantly reduced the downregulation of TrkB expression induced by the drug (Fig. 7D).

In human neuroblastoma cells, RUNX3 gene transcription has been reported to be under inhibitory control by the histone methyltransferase EZH2, the catalytic subunit of PRC2 (Wang et al., 2012). Exposure of RA-treated SH-SY5Y cells to VPA (1 mM) reduced EZH2 protein levels by 60% ± 5% (P < 0.001, N = 4) (Fig. 7E). Moreover, in these cells, TrkB downregulation induced by HDAC1 depletion was associated with a decrease of EZH2 and an increase of RUNX3 protein levels (Fig. 7F). A significant decrease of EZH2 was also observed in Kelly and LAN-1 cells following treatment with either VPA (1 mM) or entinostat (1 μM) (Supplemental Fig. 3, C and D).

To further investigate the involvement of the EZH2/RUNX3 axis in the regulation of TrkB expression, we examined the effects of the cyclopentenyl analog of 3-deazaadenosine
Fig. 6. HDAC inhibitors and HDAC1 knockdown mimic the inhibitory effect of VPA on TrkB expression and signaling. (A–C) SH-SY5Y cells were incubated for 24 hours with either vehicle, 1 mM sodium butyrate, 300 nM trichostatin A (TSA), 10 μM MC1568 (A), 1 μM entinostat (B), or 40 nM romidepsin (C). Cell lysates were then analyzed for TrkB expression. Values are the mean ± S.E.M. of four experiments. *P < 0.05; **P < 0.001 vs. the respective control (vehicle) by Student’s t test. (D) SH-SY5Y cells were incubated for 24 hours with either vehicle or 1 μM entinostat and then TrkB expression was analyzed by immunofluorescence (green color) in nonpermeabilized cells stained with an antibody directed against an extracellular domain of the receptor. Nuclei were stained in blue with DAPI. Images are representative of four independent experiments. Scale bar, 25 μm. (E and F) SH-SY5Y cells were incubated for 24 hours with either vehicle, 4 μM PCI-34051, 5 μM tubacin (E), or 1 mM valpromide (VPM) (F). Values are the mean ± S.E.M. of four experiments. (G and H) SH-SY5Y cells were preincubated for 24 hours with either vehicle, 0.5 μM entinostat (ent 0.5), 1 μM entinostat (ent 1), 20 nM romidepsin (romi 20), or 40 nM romidepsin (romi 40) and then exposed for 5 minutes to 1 nM BDNF. Values are the mean ± S.E.M. of three experiments. (I and J) SH-SY5Y cells were preincubated for 24 hours with either vehicle, 0.5 μM entinostat (ent 0.5), 1 μM entinostat (ent 1) (I), 20 nM romidepsin (romi 20), or 40 nM romidepsin (romi 40) (J) and then exposed for 5 minutes to 1 nM BDNF. Values are the mean ± S.E.M. of four experiments. ***P < 0.001 vs. control; #P < 0.05; ###P < 0.001 vs. BDNF vehicle by ANOVA followed by Newman-Keuls post hoc test. (K and L) SH-SY5Y cells were transfected with either control siRNA or HDAC1 siRNA duplexes and cell lysates were analyzed for HDAC1, H3 acetyl-Lys9/Lys14 (Ac-H3), total H3 (K), and TrkB expression (L). Each lane was loaded with a sample of an independent transfection. Values are the mean ± S.E.M. of three experiments. *P < 0.05; **P < 0.001 vs. control siRNA by Student’s t test.
Fig. 7. Involvement of RUNX3 in VPA-induced downregulation of TrkB. (A) SH-SY5Y cells were incubated with 1 mM VPA for the indicated periods of time. Zero time samples were treated with vehicle and used as control. (B) Cells were treated for 24 hours with the indicated concentrations of VPA. Cell lysates were analyzed for the protein levels of RUNX3 and H3-acetyl-Lys9/Lys14 (Ac-H3). Values are the mean ± S.E.M. of four experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle) by ANOVA followed by Newman-Keuls post hoc test. (C) SH-SY5Y cells were incubated with either vehicle or 1 mM VPA for 24 hours. Nuclear extracts were prepared and analyzed for RUNX3 and HDAC1 levels. Values are the mean ± S.E.M. of four experiments. ***P < 0.001 by Student’s t test. (D) SH-SY5Y cells transfected with either control siRNA or RUNX3 siRNA were incubated for 24 hours with either vehicle, 0.6 mM VPA (VPA 0.6), or 1 mM VPA (VPA 1.0). Cell lysates were then analyzed for RUNX3 and TrkB expression. Values are the mean ± S.E.M. of three experiments. ***P < 0.001 vs. control siRNA 1 vehicle; #P < 0.05; ###P < 0.001 vs. the corresponding value in control siRNA-treated group by Student’s t test. (E) SH-SY5Y cells were treated for 24 hours with either vehicle or 1 mM VPA. Cell lysates were analyzed for EZH2 protein levels. Values are the mean ± S.E.M. of four experiments. ***P < 0.001 by Student’s t test.
DZNep, an inhibitor of S-adenosylhomocysteine hydrolase that has been shown to deplete the cellular content of PRC2 proteins in different cell types, including human neuroblastoma cells (Varambally et al., 2002; Tan et al., 2007; Wang et al., 2012). Incubation of RA-treated SH-SY5Y cells with DZNep (1 and 5 μM) reduced EZH2 and increased RUNX3 protein levels in a concentration-dependent manner (Fig. 7G). The epigenetic changes induced by DZNep were associated with a significant suppression of TrkB expression (Fig. 7G).

**VPA Downregulates TrkB Expression and BDNF Signaling in Primary Mouse Cortical Neurons.** To assess whether TrkB expression and function was altered by VPA in a nontumoral neuronal cell model, we employed primary cultures of mouse cortical neurons. As shown in Fig. 8A, prolonged exposure (24 hours) of these cultures to either VPA (1 mM) or entinostat (1 μM) produced a significant decrease in the levels of TrkB-FL and TrkB-T. The treatment with VPA and entinostat also induced a reduced receptor autophosphorylation and Akt activation in response to BDNF (1 nM) (Fig. 8, B and C). Moreover, as observed in human neuroblastoma cells, VPA (1 mM) and entinostat (1 μM) significantly increased histone H3 acetylation, decreased EZH2 levels, and increased RUNX3 expression (Fig. 8, D–F).

**Discussion**

By inhibiting HDAC activity and promoting chromatin remodeling, VPA may affect the expression of a variety of target genes, thus extending its spectrum of action beyond the acute regulation of neurotransmission. The present study shows that in neuronal cells, prolonged in vitro exposure to VPA and other HDAC inhibitors downregulates the expression and functional activity of TrkB, a key mediator of BDNF and neurotrophin 4 actions on neuronal growth, survival, and differentiation.

The downregulation of TrkB occurred at VPA concentrations (0.6–1.0 mM) that are within the plasma concentrations associated with therapeutic effects in epilepsy (40–100 μg/ml, ~0.3–0.7 mM) (Loscher, 2002). In clinical studies investigating the antitumor efficacy of VPA, the median total and free concentrations in plasma were 1.51 and 0.61 mM, respectively (Munster et al., 2009).

VPA-induced TrkB downregulation was associated with a marked decrease in the cell surface levels of the receptor. This change is relevant because previous studies have shown that in neurons the majority of TrkB immunoreactivity is located intracellularly, whereas the cell surface receptor population is the one responsive to neurotrophins (Du et al., 2000). It was therefore important to assess whether the downregulation of cell surface TrkB induced by VPA translated into a reduction in intracellular signaling and neurotrophic responses elicited by BDNF. We found that the exposure to VPA inhibited the activation of different components of the intracellular signaling cascade triggered by BDNF via TrkB-FL, such as PLCγ1, Akt, GSK-3β, and ERK1/2. Activation of Akt and the downstream suppression of GSK-3β through phosphorylation at Ser9 are critical events for promoting cell survival (Beurel and Jope, 2006), and their inhibition by VPA correlates with the observed drug-induced impairment of BDNF protection against apoptosis triggered by serum withdrawal. Similarly, the inhibition of ERK1/2 activation may underlie the VPA ability to counteract the changes in neuronal morphology induced by BDNF, as ERK1/2 has been shown to be required for neuronal differentiation and stimulation of neurite outgrowth elicited by the neurotrophin (Encinas et al., 1999; Huang and Reichardt, 2003). Collectively, these results suggest that the VPA-induced downregulation of TrkB-FL implicates relevant consequences with regard to the efficacy of BDNF in stimulating intracellular signaling and functional responses.

TrkB-T isoforms have been proposed to modulate BDNF signaling via TrkB-FL either by sequestering the neurotrophin (Biffo et al., 1995) and/or by acting as dominant negative (Eide et al., 1996). It has also been shown that TrkB-T may regulate the cell surface expression of TrkB-FL (Haapasalo et al., 2002). On the other hand, there is evidence that TrkB-T may signal independently of TrkB-FL and during development of mammalian cerebral cortex may mediate BDNF-induced differentiation of neural stem cells toward glial progenitors and astrocytes (Cheng et al., 2007). The observation that the exposure to VPA reduces the expression of TrkB-T suggests the possibility that the drug may also impair BDNF signaling through these receptors. Additional experiments in cells that predominantly express TrkB-T, such as glia cells (Rose et al., 2003), are required specifically to address this point.

A line of evidence supports the possibility that VPA downregulates TrkB through an epigenetic mechanism involving HDAC inhibition, depletion of EZH2, and upregulation of the TrkB suppressor RUNX3. Thus, like VPA different HDAC inhibitors downregulated the expression of TrkB and curtailed BDNF-induced intracellular signaling. These effects were induced not only by sodium butyrate and trichostatin A, which, like VPA, are known to inhibit multiple HDAC isoforms, but also by the class I inhibitors romidepsin and entinostat. This finding, together with the observation that the class II inhibitor MC 1568 was without effect, suggests the involvement of class I HDACs in the negative control of TrkB expression. This possibility is also supported by the observation that cell depletion of HDAC1 by siRNA treatment mimicked the inhibitory effect of VPA on TrkB expression.

HDAC1 and HDAC2 have been shown to interact with EZH2 through the EED protein, another PRC2 core component (van der Vlag and Otte, 1999; Varambally et al., 2002), and inhibition of HDAC or EZH2 activity has been shown to induce a pharmacologic disruption of the PRC2 complex likely by promoting the proteosome-mediated degradation of its core components (Varambally et al., 2002; Fiskus et al., 2006; Tan et al., 2007; Wang et al., 2012). In agreement with these data, we found that in human neuroblastoma cell lines and mouse cortical neurons, VPA and entinostat decreased EZH2 protein levels. Moreover, in differentiated SH-SY5Y cells, a reduced EZH2 expression was also found to be associated with TrkB downregulation induced by either HDAC1 knockdown or DZNep treatment.

are the mean ± S.E.M. of four experiments. ***P < 0.001 vs. control (vehicle) by Student's t test. (F) Cells were transfected with either control siRNA or HDAC1 siRNA duplexes and cell lysates were analyzed for HDAC1, EZH2, RUNX3, and TrkB protein levels. Values are the mean ± S.E.M. of three experiments. **P < 0.05; ***P < 0.001 vs. the corresponding value in control siRNA-treated group by Student’s t test. (G) Cells were treated for 24 hours with either vehicle, 1 μM DZNep (DZNep 1), or 5 μM DZNep (DZNep 5). Cell lysates were then analyzed for EZH2, RUNX3, and TrkB expression. Values are the mean ± S.E.M. of four experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle) by Student’s t test.
EZH2 has been shown to participate in the epigenetic silencing of RUNX3 gene (Chuang and Ito, 2010) and in human neuroblastoma cells EZH2 depletion has been found to derepress RUNX3 expression (Wang et al., 2012). RUNX3 has been shown to suppress TrkB in differentiating sensory neurons (Kramer et al., 2006), and, when transfected in RA-treated neuroblastoma cells, to abrogate TrkB expression likely by direct binding to distal regulatory sequences in the TrkB gene (Inoue et al., 2007). Consistent with their ability to decrease EZH2 levels, VPA, entinostat, HDAC1 knockdown, and DZNep increased the cellular content of RUNX3. Moreover, silencing of RUNX3 gene prevented VPA-induced RUNX3 elevation and TrkB downregulation. The possibility that VPA downregulates TrkB by promoting the inhibition of TrkB gene expression through RUNX3 is also consistent with the finding that the drug caused a significant decrease in TrkB mRNA levels.

Whether VPA can regulate TrkB also through non-HDAC-dependent processes remains to be investigated. VPA has been shown to regulate intracellular pathways, such as the MEK/ERK and the PI3K/Akt/GSK-3β cascades, which are known to regulate gene transcription (Chiu et al., 2013). Importantly, these pathways commonly lead to activation of the transcription factor CREB, which has been shown to act as a positive regulator of the TrkB gene in neurons (Lei and Parada, 2007). Thus, the outcome of this process would likely be upregulation, rather than downregulation, of TrkB.

Prolonged exposure to IFN-β has been reported to downregulate TrkB expression and functional activity in differentiated SH-SY5Y cells and primary neurons (Dedoni et al., 2012). A rapid and marked decrease of cell surface expression of TrkB also occurs following treatment of neurons with BDNF (Sommerfeld et al., 2000). In the present study, we did not examine the effects of these TrkB downregulators under the same experimental conditions used for VPA, so that the relative efficacies of these different agents in suppressing TrkB were not determined.

The finding that VPA and other HDAC inhibitors downregulate TrkB expression and signaling may have important implications for the therapeutic use of these compounds, notably as antitumor agents. TrkB is highly expressed in neuroblastoma and in aggressive tumors of pancreas, prostate, and lymphoid tissue. In human neuroblastoma, the occurrence of BDNF/TrkB signaling is known to promote tumor survival, resistance to chemotherapy, anoikis, and metastasis (Nakagawara et al., 1994; Matsumoto et al., 1995; Middlemass et al., 1999; Douma et al., 2004). In neuroblastoma specimens, TrkB-FL expression has been found to be associated with MYCN gene amplification,

![Fig. 8. VPA and entinostat downregulate TrkB expression and signaling in mouse primary cortical neurons. (A) Neuronal cultures were treated with either vehicle, 1 mM VPA, or 1 μM entinostat for 24 hours, and cell extracts were analyzed for the expression of TrkB isoforms. Values are the mean ± S.E.M. of three experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle) by Student’s t test. (B and C) neurons were preincubated for 24 hours with either vehicle, 1 mM VPA, or 1 μM entinostat (ent) and then exposed for 5 minutes to either vehicle or 1 nM BDNF. Cell extracts were analyzed for phospho-Tyr706/707-TrkB (pTrkB), TrkB-FL, phospho-Akt (Thr308), and total Akt. Values are the mean ± S.E.M. of three experiments. ***P < 0.001 vs. control (vehicle); ##P < 0.01; ###P < 0.001 vs. BDNF vehicle by ANOVA followed by Newman-Keuls post hoc test. (D–F) Neurons were treated as indicated in (A) and cell extracts were then analyzed for Ac-H3, total H3, EZH2, and RUNX3 levels. Values are the mean ± S.E.M. of three separate experiments. *P < 0.05; ***P < 0.001 vs. control (vehicle) by Student’s t test.](image-url)
a negative prognostic marker of this tumor (Nakagawara et al., 1994). Preclinical studies have demonstrated that HDAC inhibitors possess potent anticancer activity for highly malignant tumors, such as neuroblastoma (Witt et al., 2009; West and Johnstone, 2014). The present study suggests that VPA and class I HDAC inhibitors may be particularly useful for treating aggressive tumors expressing TrkB.

In differentiated SH-SY5Y cells, the expression of TrkA was not significantly affected by VPA, whereas the protein levels of TrkC and p75NTR were markedly elevated by the drug. This indicates that VPA treatment differentially affected neurotrophin receptor expression. Interestingly, the expression of TrkC is a favorable prognostic factor in neuroblastomas (Yamashiro et al., 1996; Ryden et al., 1996) and medulloblastomas (Segal et al., 1994). Unlike TrkA and TrkB, both p75NTR and TrkC have been shown to act as dependence receptors, which in the absence of the ligand trigger apoptotic cell death (Bouzas-Rodriguez et al., 2010). Thus, their induction by VPA may constitute an additional mechanism supporting the antitumor action of this drug.

We observed that VPA and entinostat downregulated TrkB expression and signaling also in mouse primary cortical neurons and altered EZH2 and RUNX3 protein levels in a manner similar to that observed in human neuroblastoma cells. These results suggest that the drugs are able to affect the epigenetic control of TrkB expression also in nontumor neuronal cells and independently of cell pretreatment with RA. The functional significance of VPA-induced TrkB downregulation in cortical neurons remains to be established. TrkB inhibition is considered a potential therapeutic target for some central nervous system-related disorders, such as epilepsy and neuropathic pain, which are effectively treated with VPA (Bouille et al., 2012). Additional studies are required to investigate whether the downregulation of TrkB contributes to the beneficial effects of VPA in these neurologic diseases.

Authorship Contributions

Participated in research design: Dedoni, Olianas, Ingiglietti, Onali. Conducted experiments: Dedoni, Marras, Olianas. Performed data analysis: Dedoni, Marras, Olianas. Wrote or contributed to the writing of the manuscript: Dedoni, Olianas, Ingiglietti, Onali.

References

Astry AR and Monteggia LM (2012) Brain-derived neurotrophic factor and neuro psychiatric disorders. Pharmacol Rev 64:239–255. Balsalobre-Samanian S, Ramos J, Luu W, Srinawad M, Verner E, and Buggy JJ (2008) A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22:1026–1034. Bardai FH, Price V, Zaayman M, Wang L, and D’Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, and Buggy JJ (2008) Inhibition of TrkB contributes to the beneficial effects of VPA in these disorders. Mol Cancer Ther 7:779–789.

Inotropic-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis. J Clin Invest 120:850–858. Cesca F, Baldelli P, Valtorta F, and Benfenati F (2010) The synapsins: key actors of synapse function and plasticity. Prog Neurobiol 91:333–348. Chao MV (2003) Neurotrophins and their receptors: a convergence point for many signaling pathways. Nat Rev Neurosci 4:299–309. Chateauneuf S, Moreau F, Diacoo M, and Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010:1–14. Cheng A, Coksaygan T, Tang H, Khatri B, Balice-Gordon RJ, Rao MS, and Mattson MP (2007) Truncated tyrosine kinase B brain-derived neurotrophic factor receptor directly directs cortical neural stem cells to a glioma cell fate by a novel signaling mechanism. J Neurochem 100:1515–1530. Chiu C-T, Wang Z, Hunsberger JG, and Chuang DM (2013) Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 65:155–142. Chuang LSH and Ito Y (2010) RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 29:2605–2615. Dedoni S, Olianas MC, Ingiglietti A, and Oliani P (2012) Interferon-α inhibits neurotrophin 3 signaling and pro-survival activity by upregulating the expression of truncated TrkC-T1 receptor. Mol Neurobiol 54:1825–1845. Dedoni S, Olianas MC, and Oliani P (2010) Interferon-γ induces apoptosis in human SH-SY5Y neuroblastoma cells and mouse primary cortical neurons. J Neurochem 112:58–68. Encinas M, Iglesias M, Llecha N, and Comella JX (1999) Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neurogenesis of the neuroblastoma cell line SH-SY5Y. J Neurosci 19:1409–1421. Fiskus W, Prampat M, Balas M, Herber B, Rao R, Chinnaiyan A, Atadja P, and Bialla K (2006) Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 5:3096–3109. Fujii S, Ito K, Ito Y, and Ochiai A (2008) Enhancer of zeste homologue 2 (EZH2) downregulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283:17234–172332. Fukuchi M, Nii T, Ishimaru N, Minamino A, Hara D, Takasaki I, Tabuchi A, and Tsuda M (2009) Valproic acid induces up- or down-regulation of gene expressions responsible for the maintenance of cell proliferation and apoptosis in rat cortical neurons through its epigenetic actions. Neurosci Res 65:35–43. Garner CC and Matus A (1988) Different forms of microtubule-associated protein 2 are expressed by separate cell fate transcripts. J Cell Biol 107:779–787.

Göttlicher M, Minucci S, Zha P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969–6978. Haapasalo A, Sipola I, Larsson K, Akerman KEO, Stolpov P, Stamm S, Wong G, and Castren E (2002) Regulation of TRKB surface expression by brain derived neurotrophic factor and truncated TRBb3 isorforms. J Biol Chem 277:43160–43167. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, and Schreiber SL (2003) Domain–domain interactions are required for Runx transcription factor signaling in dorsal root ganglion sensory neuron development. J Pharmacol Exp Ther 307:730–738. Huang EJ and Reichardt LF (2003) Trk receptors: roles in neuronal signal transduction. Ann Rev Biochem 72:609–642. Inoue K, Ito K, Osato M, Lee B, Bae SC, and Ito Y (2007) The transcription factor Runx3 represses the neurotrophin receptor TrkB during lineage commitment of dorsal root ganglion neurons. J Biol Chem 282:24175–24184. Kaplan DR, Matsutomo K, Lucarelli E, and Thiele CJ; Eukaryotic Signal Transduction Group (1993) Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. J Cell Biol 120:282–296. Loscher W (2002) Basic pharmacology of valporate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16:699–694. MacLeod MR, Allopp TE, McCutie J, and Kelly JS (2001) Serum withdrawal causes differentiation and class I HDAC inhibitors may be particularly useful for treating aggressive tumors expressing TrkB. In differentiated SH-SY5Y cells, the expression of TrkB was not significantly affected by VPA, whereas the protein levels of TrkC and p75NTR were markedly elevated by the drug. This indicates that VPA treatment differentially affected neurotrophin receptor expression. Interestingly, the expression of TrkC is a favorable prognostic factor in neuroblastomas (Yamashiro et al., 1996; Ryden et al., 1996) and medulloblastomas (Segal et al., 1994). Unlike TrkA and TrkB, both p75NTR and TrkC have been shown to act as dependence receptors, which in the absence of the ligand trigger apoptotic cell death (Bouzas-Rodriguez et al., 2010). Thus, their induction by VPA may constitute an additional mechanism supporting the antitumor action of this drug.

We observed that VPA and entinostat downregulated TrkB expression and signaling also in mouse primary cortical neurons and altered EZH2 and RUNX3 protein levels in a manner similar to that observed in human neuroblastoma cells. These results suggest that the drugs are able to affect the epigenetic control of TrkB expression also in nontumor neuronal cells and independently of cell pretreatment with RA. The functional significance of VPA-induced TrkB downregulation in cortical neurons remains to be established. TrkB inhibition is considered a potential therapeutic target for some central nervous system-related disorders, such as epilepsy and neuropathic pain, which are effectively treated with VPA (Bouille et al., 2012). Additional studies are required to investigate whether the downregulation of TrkB contributes to the beneficial effects of VPA in these neurologic diseases.

Downloaded from jpet.aspetjournals.org at ASBET Journals on November 15, 2022
Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, and Thiele CJ (1995) Expression of brain-derived neurotrophic factor and p140TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 55:1798–1806.

McAllister AK, Katz LC, and Lo DC (1999) Neurotrophins and synaptic plasticity. Annu Rev Neurosci 22:295–318.

Middlemas DS, Kihl RK, Zhou J, and Zhu X (1999) Brain-derived neurotrophic factor promotes survival and chemoprotection of human neuroblastoma cells. J Biol Chem 274:16451–16460.

Munster P, Marchion D, Bizaku E, Laecke M, Kim J, Centeno B, Daud A, Neuger A, McAllister AK, Katz LC, and Lo DC (1999) Neurotrophins and synaptic plasticity. Annu Rev Neurosci 22:295–318.

Munster P, Marchion D, Bizaku E, Laecke M, Kim J, Centeno B, Daud A, Neuger A, McAllister AK, Katz LC, and Lo DC (1999) Neurotrophins and synaptic plasticity. Annu Rev Neurosci 22:295–318.

Nakagawara A, Azar CG, Souvarda NJ, and Brodeur GM (1994) Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14:759–767.

Nalivaeva NN, Belyaev ND, and Turner AJ (2009) Sodium valproate: an old drug with new roles. Trends Pharmacol Sci 30:509–514.

Park H and Poo MM (2013) Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 14:7–23.

Phiel CJ, Zhang F, Huang ET, Guenther MG, Lazar MA, and Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticluensing agent. Mol Cell 7:4592–4597.

Phiel CJ, Zhang F, Huang ET, Guenther MG, Lazar MA, and Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticluensing agent. Mol Cell 7:4592–4597.

Rettig I, Koeneke E, Trippel F, Mueller WC, Burhonne J, Kopp-Schneider A, Faibian J, Schober A, Perneckov U, von Deinsing A, et al. (2015) Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis 6:e1657.

Rosc CR, Blum R, Fichler B, Lapiar A, Kafitz KW, and Konnerth A (2003) Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells. Nature 426:74–78.

Rydén M, Sehgal R, Dominici C, Schilling FH, Ibáñez CF, and Kogner P (1996) Expression of mTrkA for the neurotrophin receptor trkA in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer 74:773–779.

Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, and Nakashis O (1999) A synthetic inhibitor of histone deacetylase, MS-27275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96:4592–4597.

Segal RA, Goumnerova LC, Kwon YK, Stiles CD, and Pomeroy SL (1994) Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 91:12867–12871.

Sommerfeld MT, Schweigreiter R, Barde Y-A, and Hoppe E (2000) Down-regulation of the neurotrophin receptor TrkB following ligand binding. Evidence for an involvement of the proteasome and differential regulation of TrkA and TrkB. J Biol Chem 275:8982–8990.

Stoiber F, Castren E, and Stamm S (2002) Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem Biophys Res Commun 290:1054–1065.

Subramanian C, Jarzembojskova JA, Opipari AW Jr, Castle VP, and Kroc BPS (2011) HDAC6 deacetylases Ku70 and regulates Ku70-Bax binding in neuroblastoma. Neoplasia 13:726–734.

Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RKM, Tan BPO, Liu ET, and Yu Q (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21:1050–1063.

Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, and Pente JF (2003) Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983:84–100.

van der Vlag J and Otte AP (1999) Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23:474–478.

Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sandra MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629.

Wang C, Liu Z, Wuo CW, Li Z, Wang L, Wei JS, Marquez VR, Bates SE, Jin Q, Khan J, et al. (2012) EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX1, and NGFR. Cancer Res 72:315–324.

West AC and Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124:30–39.

Witt O, Deubzer HE, Lodrini M, Milde T, and Oehme I (2009) Targeting histone deacetylases in neuroblastoma. J Biol Chem 284:27876–27883.

Yasuda S, Liang MH, Marinova Z, Yahyavi A, and Chuang D-M (2009) The mood stabilizer lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14:51–58.

Address correspondence to: Pierluigi Onali, Department of Biomedical Sciences, Section of Neuroscience, Cittadella Universitaria di Monserrato, 09042 Monserrato (CA), Italy. E-mail: onali@unic.it
**Authors:** Simona Dedoni, Luisa Marras, Maria C. Olianas, Angela Ingianni, and Pierluigi Onali

**Title:** “Down-regulation of TrkB expression and signalling by valproic acid and other histone deacetylase inhibitors

**Journal:** *The Journal of Pharmacology and Experimental Therapeutics*

---

**Supplemental Data**

**Supplemental Fig. 1**

Induction of TrkB expression by RA in LAN-1 and Kelly human neuroblastoma cells. Cells were incubated for 6 days in the presence of either vehicle (0.1 % dimethyl sulfoxide) (-RA) or 10 µM RA (+RA). Cell lysates were analyzed for TrkB and actin protein levels. Western blot data are representative of four independent experiments.
Effects of HDAC inhibitors on histone H3 acetylation in differentiated SH-SY5Y cells.

A-D: cells were incubated for the indicated periods of time with either 1 mM valproic acid (VPA) (A), 300 nM trichostatin A (TSA) (B), 1 μM entinostat (C) or 10 μM MC1568. Zero time samples were treated with vehicle. Values are the mean ± SEM of four experiments. *** P < 0.001 vs control (zero time) by ANOVA followed by Newman-Keuls post hoc test.

E: cells were incubated for 24 h with either vehicle, 40 nM romidepsin, 1 mM sodium butyrate (NaButyr), 4 μM PCI-34051, 5 μM tubacin or 1 mM valpromide (VPM). Cell lysates were analyzed for H3- acetyl-Lys9/Lys14 (Ac-H3) and total H3. Values are the mean ± SEM of three experiments.*** P < 0.001 vs control (vehicle) by Student’s t test.

Supplemental Fig. 2
Effects of VPA and entinostat on RUNX3 and EZH2 expression in Kelly and LAN-1 human neuroblastoma cells. Kelly (A and C) and LAN-1 (B and D) were exposed for 24 h to either vehicle, 1 mM VPA or 1 µM entinostat. Cell lysates were analyzed for RUNX3 and EZH2 protein levels. Values are the mean ± SEM of four experiments.

* $P < 0.05$, *** $P < 0.001$ vs control (vehicle) by Student’s t test.